Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis (Review)

Oncology Letters

Volumn 10, Issue 3, 2015, Pages 1240-1250

  Ye, Lin ^a   Jia, Yongning ^a,b   Ji, Ke ^a   Sanders, Andrew J ^a   Xue, Kan ^b   Ji, Jiafu ^b   Mason, Malcolm D ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Cancer; Metastasis; Therapy; Traditional Chinese medicine

Indexed keywords

ASTRAGALUS ROOT; CANTHARIDIN; CHINESE DRUG; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ANGIOGENESIS; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL CYCLE ARREST; CHINESE MEDICINE; COLORECTAL CANCER; GASTROINTESTINAL TOXICITY; GINSENG; GROWTH INHIBITION; HUMAN; LEUKOPENIA; LIVER TOXICITY; META ANALYSIS (TOPIC); METASTASIS; MORTALITY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84937407794     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3459     Document Type: Review

References (104)

1. NahinRL, BarnesPM, StussmanBJ and BloomB:Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report: 1-14, 2009.
2. KlempnerSJ and BubleyG: Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist17: 830-837, 2012.
3. GraysonM: Traditional Asian Medicine. Nature480: S81, 2011.
4. ChenGQ, ZhuJ, ShiXG, etal: Invitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood88: 1052-1061, 1996.
5. CaiXZ: Observation of therapeutic effect of single-dose combined administration of Qinghaosu, sulphomethoxine, pyrimethamine and primaquine in the treatment of chloroquine-resistant malignant malaria (author's transl). Zhonghua Nei Ke Za Zhi20: 724-727, 1981 (InChinese).
6. KangSH, JeongSJ, KimSH, etal: IcarisideII induces apoptosis in U937 acute myeloid leukemia cells: role of inactivation of STAT3-related signaling. PLoS One7: e28706, 2012.
7. HeR, MottBT, RosenthalAS, GennaDT, PosnerGH and Arav-BogerR: An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities. PLoS One6: e24334, 2011.
8. FirestoneGL and SundarSN: Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med11: e32, 2009.
9. LaiH, NakaseI, LacosteE, SinghNP and SasakiT: Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res29: 3807-3810, 2009.
10. SunWC, HanJX, YangWY, DengDA and YueXF: Antitumor activities of 4 derivatives of artemisic acid and artemisinin B invitro. Zhongguo Yao Li Xue Bao13: 541-543, 1992 (InChinese).
11. ZhangSY, GuCH and GaoXD: A randomly double-blinded and multicentre study of chemotherapy assisted Yangzhengxiaoji capsule on treating primary hepatic carcinoma. J Diffic Compl Case8: 461-464, 2009.
12. JiangWG, YeL, JiK, etal: Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: the pivotal role of focal adhesion kinase signalling. Oncol Rep30: 1405-1413, 2013.
13. YeL, JiK, FrewerN, JiJ and JiangWG: Impact of Yangzheng Xiaoji on the adhesion and migration of human cancer cells: the role of the AKT signalling pathway. Anticancer Res32: 2537-2543, 2012.
14. JiangWG, YeL, JiK, FrewerN, JiJ and MasonMD: Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway. Int J Oncol41: 1635-1642, 2012.
15. KonkimallaVB and EfferthT: Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol116: 207-210, 2008.
16. No authors listed: Astragalus membranaceus. Monograph. Altern Med Rev8: 72-77, 2003.
17. HofsethLJ and WargovichMJ: Inflammation, cancer, and targets of ginseng. J Nutr137 (Suppl1): 183S-185S, 2007.
18. WangGS: Medical uses of Mylabris in ancient China and recent studies. J Ethnopharmacol26: 147-162, 1989.
19. LuCX, NanKJ and LeiY: Agents from amphibians with anticancer properties. Anticancer Drugs19: 931-939, 2008.
20. ShuklaY and KalraN: Cancer chemoprevention with garlic and its constituents. Cancer Lett247: 167-181, 2007.
21. Kuttan R, Bhanumathy P, Nirmala K and George MC: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett29: 197-202, 1985.
22. Wang GS: Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 26: 147-162, 1989.
23. LeeTK, JohnkeRM, AllisonRR, O'BrienKF and Dobbs LJJr: Radioprotective potential of ginseng. Mutagenesis20: 237-243, 2005.
24. LiuD and ChenZ: The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem9: 392-396, 2009.
25. YoshidaY, WangMQ, LiuJN, ShanBE and YamashitaU: Immunomodulating activity of Chinese medicinal herbs and Oldenlandiadiffusa in particular. Int J Immunopharmacol19: 359-370, 1997.
26. WangY, QianXJ, HadleyHR and LauBH: Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma. Mol Biother4: 143-146, 1992.
27. LiuJ, ShiZ, XuZ, etal: Clinical observation on treatment of non-parvicellular carcinoma of the lung with jin fu kang oral liquid. J Tradit Chin Med20: 96-100, 2000.
28. McCullochM, SeeC, ShuXJ, etal: Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. JClin Oncol24: 419-430, 2006.
29. YunTK and ChoiSY: Preventive effect of ginseng intake against various human cancers: a case-control study on 1987pairs. Cancer Epidemiol Biomarkers Prev4: 401-408, 1995.
30. WuP, DugouaJJ, EyawoO, MillsEJ: Traditional Chinese Medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res28: 112, 2009.
31. ChenM, MayBH, ZhouIW, XueCC and ZhangAL: FOLFOX4 combined with herbal medicine for advanced colorectal cancer: a systematic review. Phytother Res28: 976-991, 2014.
32. WangZ, WenJ, ZhangJ, YeM and GuoD: Simultaneous determination of four bufadienolides in human liver by high-performance liquid chromatography. Biomed Chromatogr18: 318-322, 2004.
33. WangJ, JinY, XuZ, ZhengZ and WanS: Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in A 549cells. Exp Biol Med (Maywood) 234: 566-572, 2009.
34. WangDL, QiFH, XuHL, etal: Apoptosis-inducing activity of compounds screened and characterized from cinobufacini by bioassay-guided isolation. Mol Med Rep3: 717-722, 2010.
35. QiFH, LiAY, LvH, etal: Apoptosis-inducing effect of cinobufacini, Bufo bufo gargarizans Cantor skin extract, on human hepatoma cell line BEL-7402. Drug Discov Ther2: 339-343, 2008.
36. QiF, LiA, ZhaoL, etal: Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J Ethnopharmacol128: 654-661, 2010.
37. CuiX, InagakiY, XuH, etal: Anti-hepatitisB virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15cells. Biol Pharm Bull33: 1728-1732, 2010.
38. MengZ, YangP, ShenY, etal: Pilot study of Huachansu in patients with hepatocellular carcinoma, non-small cell lung cancer, or pancreatic cancer. Cancer115: 5309-5318, 2009.
39. QinTJ, ZhaoXH, YunJ, ZhangLX, RuanZP and PanBR: Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol14: 5210-5216, 2008.
40. XieX, HuangX, LiJ, etal: Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: a meta-analysis. Med Hypotheses81: 243-250, 2013.
41. DongJ, SuSY, WangMY and ZhanZ: Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res29: 137, 2010.
42. DaiZ, WanX, KangH, etal: Clinical effects of shenqi fuzheng injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets. J Tradit Chin Med28: 34-38, 2008.
43. YangAK, HeSM, LiuL, LiuJP, WeiMQ and ZhouSF: Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Cur Med Chem17: 1635-1678, 2010.
44. LuY, WuLQ, DongQ and LiCS: Experimental study on the effect of Kang-Lai-Te induced apoptosis of human hepatoma carcinoma cell HepG2. Hepatobiliary Pancreat Dis Int8: 267-272, 2009.
45. GuoHY, CaiY, YangXM, etal: Randomized phaseII trial on mitomycin-C/cisplatin +/-KLT in heavily pretreated advanced breast cancer. Am J Chin Med36: 665-674, 2008.
46. LiuX, XuF, WangG, DiaoX and LiY: Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: A systematic review and meta-analysis. Curr Ther Res Clin Exp69: 381-411, 2008.
47. WangQL, XueCM, WuSP, LiYX and BiXJ: Clinical observation on Yangzhengxiaoji capsule in treatment of 60cases of moderate to severe degree atypical proliferation of gastric mucosa. Chin J Diffic Compl Case7: 38-39, 2008 (InChinese).
48. XueK, ShanF and JiJ: Meta-analysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis. Chin J Clin Oncol40: 1318-1323, 2013.
49. Chinese Pharmacopoeia Commission: Pharmacopoeia of the People's Republic of China 2010. Vol 1. 9th edition. Chemical Industry Press, Beijing, 2011.
50. LiT, TamadaK, AbeK, etal: The restoration of the antitumor T cell response from stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki-to (TJ-41:Bu-Zhong-Yi-Qi-Tang). Immunopharmacology43: 11-21, 1999.
51. NiwaK, HashimotoM, MorishitaS, etal: Preventive effects of Juzen-taiho-to on N-methyl-N-nitrosourea and estradiol-17beta-induced endometrial carcinogenesis in mice. Carcinogenesis22: 587-591, 2001.
52. KamiyamaH, TakanoS, IshikawaE, TsuboiK and MatsumuraA: Anti-angiogenic and immunomodulatory effect of the herbal medicine 'Juzen-taiho-to' on malignant glioma. Biol Pharm Bull28: 2111-2116, 2005.
53. SaikiI: A Kampo medicine 'Juzen-taiho-to'-prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull23: 677-688, 2000.
54. OhnishiY, FujiiH, HayakawaY, etal: Oral administration of a Kampo (Japanese herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells. Jpn J Cancer Res89: 206-213, 1998.
55. MatsumotoM, SeyaT, KikkawaS, etal: Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCGcell wall skeleton. Int Immunopharmacol1: 1559-1569, 2001.
56. Miyagami M and Katayama Y: Improvement of host-immunity by adjuvant therapy with juzen-taiho-to for patients with brain tumors. No Shinkei Geka31: 401-409, 2003 (In Japanese).
57. NgoSN, WilliamsDB, CobiacL and HeadRJ: Does garlic reduce risk of colorectal cancer? A systematic review. J Nutr137: 2264-2269, 2007.
58. SundaramSG and MilnerJA: Diallyl disulfide inhibits the proliferation of human tumor cells in culture. Biochim Biophys Acta1315: 15-20, 1996.
59. NishinoH, IwashimaA, ItakuraY, MatsuuraH and FuwaT: Antitumor-promoting activity of garlic extracts. Oncology46: 277-280, 1989.
60. AroraA and ShuklaY: Induction of apoptosis by diallyl sulfide in DMBA-induced mouse skin tumors. Nutr Cancer44: 89-94, 2002.
61. AroraA, SiddiquiIA and ShuklaY: Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Mol Cancer Ther3: 1459-1466, 2004.
62. KaoST, YehCC, HsiehCC, etal: The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. Life Sci69: 1485-1496, 2001.
63. ZhuK, FukasawaI, FurunoM, etal: Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol97: 405-409, 2005.
64. OkitaK, LiQ, MurakamioT and TakahashiM: Anti-growth effects with components of Sho-saiko-to (TJ-9) on cultured human hepatoma cells. Eur J Cancer Prev2: 169-175, 1993.
65. ChangWH, ChenCH and LuFJ: Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines. Planta Med68: 128-132, 2002.
66. ChangWH, ChenCH, GauRJ, etal: Effect of baicalein on apoptosis of the human Hep G2 cell line was induced by mitochondrial dysfunction. Planta Med68: 302-306, 2002.
67. MotooY and SawabuN: Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Lett86: 91-95, 1994.
68. MatsuzakiY, KurokawaN, TeraiS, MatsumuraY, KobayashiN and OkitaK: Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn J Cancer Res87: 170-177, 1996.
69. YanoH, MizoguchiA, FukudaK, etal: The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res54: 448-454, 1994.
70. XiaoD, Herman-AntosiewiczA, AntosiewiczJ, etal: Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc25C. Oncogene24: 6256-6268, 2005.
71. SinghSV: Impact of garlic organosulfides on p21(H-ras) processing. J Nutr131: 1046S-1048S, 2001.
72. BonnessK, AragonIV, RutlandB, Ofori-AcquahS, DeanNM and HonkanenRE: Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aalpha. Mol Cancer Ther5: 2727-2736, 2006.
73. KohnoT, MatsudaE, SasakiH and SasakiT: Protein-tyrosine kinase CAKbeta/PYK2 is activated by binding Ca2+/calmodulin to FERM F2 alpha2 helix and thus forming its dimer. BiochemJ410: 513-523, 2008.
74. GilmoreAP and RomerLH: Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell7: 1209-1224, 1996.
75. CaiJ, ParrC, WatkinsG, JiangWG and BoultonM: Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res12: 3510-3517, 2006.
76. BrarenR, HuH, KimYH, BeggsHE, ReichardtLF and WangR: Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation. J Cell Biol172: 151-162, 2006.
77. OchiaiK, TakitaS, EirakuT, etal: Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem20: 1644-1658, 2012.
78. FolkmanJ: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov6: 273-286, 2007.
79. PotenteM, GerhardtH and CarmelietP: Basic and therapeutic aspects of angiogenesis. Cell146: 873-887, 2011.
80. YeB, AponteM, DaiY, etal: Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence. Cancer Lett251: 43-52, 2007.
81. PapadopoulosVKapsisA, LiH, etal: Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells. Anticancer Res20: 2835-2847, 2000.
82. ChaoJC and ChuCC: Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World J Gastroenterol10: 37-41, 2004.
83. KimKS, RheeKH, YoonJH, LeeJG, LeeJH and YooJB: Ginkgo biloba extract (EGb761) induces apoptosis by the activation of caspase-3 in oral cavity cancer cells. Oral Oncol41: 383-389, 2005.
84. KoltermannA, LieblJ, FürstR, AmmerH, VollmarAM and ZahlerS: Ginkgo biloba extract EGb761 exerts anti-angiogenic effects via activation of tyrosine phosphatases. J Cell Mol Med13: 2122-2130, 2009.
85. TangPM, ChanJY, ZhangDM, etal: Pheophorbidea, an active component in Scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2. Cancer Biol Ther6: 504-509, 2007.
86. GohD, LeeYH and OngES: Inhibitory effects of a chemically standardized extract from Scutellaria barbata in human colon cancer cell lines, LoVo. J Agric Food Chem53: 8197-8204, 2005.
87. YinX, ZhouJ, JieC, XingD and ZhangY: Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549. Life Sci75: 2233-2244, 2004.
88. PerezAT, ArunB, TripathyD, etal: A phase1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat120: 111-118, 2010.
89. DaiZJ, LuWF, GaoJ, etal: Anti-angiogenic effect of the total flavonoids in Scutellaria barbata D. Don. BMC Complement Altern Med13: 150, 2013.
90. ShiauAL, ShenYT, HsiehJL, WuCL and LeeCH: Scutellaria barbata inhibits angiogenesis through downregulation of HIF-1 α in lung tumor. Environ Toxicol29: 363-370, 2014.
91. WeiL, LinJ, XuW, etal: Scutellaria barbata D. Don inhibits tumor angiogenesis via suppression of hedgehog pathway in a mouse model of colorectal cancer. Int J Mol Sci13: 9419-9430, 2012.
92. ZhaoD, QinC, FanX, LiY and GuB: Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells. Eur J Pharmacol723: 360-367, 2014.
93. Bellou S, Pentheroudakis G, Murphy C and Fotsis T: Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett338: 219-228, 2013.
94. BoschFX and de SanjoséS: The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers23: 213-227, 2007.
95. ZhangKH and XieJF: Experimental study on the treatment of oral precancerous lesion-short and long term effect of tablet AnticancerII. Ann Acad Med Singapore18: 528-532, 1989.
96. LuB, XuL, YuL and ZhangL: Extract of radix curcumae prevents gastric cancer in rats. Digestion77: 87-91, 2008.
97. VolateSR, DavenportDM, MugaSJ and WargovichMJ: Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis26: 1450-1456, 2005.
98. HouJ, LinPZ, ChenZF, etal: Field population-based blocking treatment of esophageal epithelia dysplasia. World J Gastroenterol8: 418-422, 2002.
99. DingZ, GaoF and LinP: Long-term effect of treating patients with precancerous lesions of the esophagus. Zhonghua Zhong Liu Za Zhi21: 275-277, 1999 (In Chinese).
100. SunZ, GuanX, LiN, LiuX and ChenX: Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncol46: 105-110, 2010.
101. OhWK, KantoffPW, WeinbergV, etal: Prospective, multicenter, randomized phaseII trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol22: 3705-3712, 2004.
102. OlakuO, ZiaF, SantanaJM and WhiteJD: The National Cancer Institute best case series program: a summary of cases of cancer patients treated with unconventional therapies in India. Integr Cancer Ther12: 385-392, 2013.
103. ZiaFZ and WhiteJD: National Cancer Institute Best Case Series program. Integr Cancer Ther8: 113-114, 2009.
104. OlakuO and WhiteJD: Herbal therapy use by cancer patients: a literature review on case reports. Eur J Cancer47: 508-514, 2011.